💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Daunorubicin Citrate

CHEMBL1200475 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
719.6 g/mol
LogP
—
Phase
4

A citrate salt form of daunorubicin with similar chemotherapy properties to the parent compound, used in the treatment of acute leukemias. Like other anthracyclines, it intercalates into DNA and inhibits topoisomerase II. Cumulative cardiotoxicity remains a major dose-limiting concern.

Molekularmasse

719,6000 g/mol

TPSA

318,00 Ų

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Cardiovascular Disease Respiratory Disease Pain Management Non-Small Cell Lung Cancer Chronic Obstructive Pulmonary Disease Alzheimer's Disease Parkinson's Disease Infectious Disease Melanoma Gastroesophageal Reflux Disease Inflammatory Bowel Disease Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Hyperlipidemia Lymphoma Type 2 Diabetes Hypertension Breast Cancer Chronic Pain HIV/AIDS Prostate Cancer Colorectal Cancer Leukemia

Wirkmechanismus

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1.O=C(O)CC(O)(CC(=O)O)C(=O)O

                

                

                
                

                    
InChI

                    
InChI=1S/C27H29NO10.C6H8O7/c1-10-22(30)14(28)7-17(37-10)38-16-9-27(35,11(2)29)8-13-19(16)26(34)21-20(24(13)32)23(31)12-5-4-6-15(36-3)18(12)25(21)33;7-3(8)1-6(13,5(11)12)2-4(9)10/h4-6,10,14,16-17,22,30,32,34-35H,7-9,28H2,1-3H3;13H,1-2H2,(H,7,8)(H,9,10)(H,11,12)/t10-,14-,16-,17-,22+,27-;/m0./s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C33H37NO17

                    

                    
                    

                        
HBD / HBA

                        
9 / 18

                    

                    
                    

                        
Rotierbare Bindungen

                        
9

                    

                    
                    
                    

                        
Schwere Atome

                        
51

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
A citrate salt form of daunorubicin with similar chemotherapy properties to the parent compound, used in the treatment of acute leukemias. Like other anthracyclines, it intercalates into DNA and inhibits topoisomerase II. Cumulative cardiotoxicity remains a major dose-limiting concern.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Inhibits DNA topoisomerase, preventing the relaxation of supercoiled DNA during replication and transcription. This causes DNA strand breaks and triggers apoptosis in rapidly dividing cells.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Daunorubicin Citrate is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1200475.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 9961878.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.